A Resin From the Earth's Dry Margins
Boswellia trees grow in some of the world's most inhospitable terrain — the dry, rocky hillsides and limestone plateaus of India, Pakistan, the Arabian Peninsula, and the Horn of Africa. They are medium-to-large deciduous trees of the family Burseraceae, capable of growing directly from rock faces with minimal soil. Their resilience in harsh conditions is mirrored by the extraordinary endurance of their cultural and medicinal legacy.
The resin — frankincense — is obtained by making deliberate incisions in the bark with a tool called a mingaf. The milky-white sap bleeds out, oxidizes in contact with air, and hardens over 10–20 days into the amber-colored "tears" (solidified resin drops) that have been traded and burned in temples for millennia. A healthy tree can be tapped multiple times per year, though sustainable harvesting requires careful management to avoid long-term damage to the tree.
Frankincense in the Ancient World
Ancient Egypt (c. 3000 BCE and earlier)
The ancient Egyptians were among the earliest documented users of frankincense. Hieroglyphic records and archaeological evidence confirm it was used in temple rituals dedicated to Ra and other deities, as an embalming agent in mummification, as a component of kohl eyeliner, and in medicinal preparations. Egyptian texts reference "sntr" — identified by Egyptologists as frankincense — in contexts suggesting both sacred and therapeutic application.
Queen Hatshepsut's famous expedition to the Land of Punt (approximately 1480 BCE, depicted in detail at Deir el-Bahri) was partly motivated by obtaining frankincense trees. She had living boswellia trees transported back to Egypt for cultivation near her mortuary temple — possibly the first recorded attempt at boswellia cultivation.
The Incense Road
At its height (roughly 300 BCE – 300 CE), the Incense Road was one of antiquity's great trading networks, stretching 2,000 miles from the frankincense-producing regions of southern Arabia (modern Yemen and Oman) and the Horn of Africa northward through the Arabian Peninsula to the Mediterranean world. Cities like Petra (the Nabataean capital in modern Jordan) and Palmyra grew wealthy as waypoints on this route.
The scale of trade was enormous. Roman historian Pliny the Elder, writing in the 1st century CE, complained that trade with Arabia and India was draining Roman gold — and estimated that Arabia grew wealthy largely from frankincense and myrrh exports to the Roman Empire. He estimated 3,000 talents (approximately 78,000 kg) of frankincense were burned annually in the Empire. The UNESCO-recognized "Land of Frankincense" in Oman's Dhofar region preserves the archaeological remains of this trade, including the ancient port of Sumhuram and the frankincense groves of Wadi Dawkah.
Mesopotamia and the Hebrew Bible
Frankincense appears throughout ancient Mesopotamian religious texts as an offering to the gods. In the Hebrew Bible (Old Testament), it is one of the four ingredients of the sacred incense (ketoret) burned in the Tabernacle and the Temple in Jerusalem (Exodus 30:34). The gift of frankincense to the infant Jesus by the Magi (Matthew 2:11) drew on its established sacred status. Jewish priestly families kept detailed records of frankincense use in Temple rituals; some of this knowledge is preserved in the Talmud.
Ancient Greece and Rome
Greek physician Pedanius Dioscorides (~40–90 CE) described frankincense in his monumental work De Materia Medica — the foundational pharmacological reference of the ancient world, used for over 1,500 years after his death. He documented its use for treating ulcers, hemorrhages, tumors, and fevers. Galen (~129–216 CE), the most influential physician of the Roman period, also wrote of frankincense's medicinal properties.
Boswellia in Ayurvedic Medicine
In the Indian subcontinent, Boswellia serrata — known as Shallaki (Sanskrit) or Salai guggul — has a documented place in the Ayurvedic system of medicine that spans from at least the early classical period of Ayurveda (roughly 600 BCE – 700 CE, though some texts may be older). Classical Ayurvedic texts including the Charaka Samhita and Sushruta Samhita reference shallaki for inflammatory joint conditions and as a component of medicated ghee preparations.
In Ayurvedic pharmacology, shallaki is classified as:
- A Rasayana — a rejuvenative herb believed to promote longevity and vitality
- A Vedana-sthapana — an analgesic
- A Shothahara — an anti-inflammatory agent
It was traditionally prepared as a decoction, as a medicated ghee (for enhanced fat-soluble compound absorption — a method that presaged modern understanding of boswellic acid bioavailability), and as a topical paste for joint conditions. Its primary Ayurvedic applications included Amavata (a condition corresponding to rheumatoid arthritis), Sandhivata (osteoarthritis), and respiratory conditions including bronchial asthma.
Traditional Chinese and Middle Eastern Use
In Traditional Chinese Medicine (TCM), frankincense resin — called Rǔxiāng (乳香) — has been used since at least the Tang Dynasty (618–907 CE). It appears in classical TCM texts as an agent that "moves blood" and alleviates pain, used in formulas for traumatic injuries, arthritic conditions, menstrual pain, and skin ulcers. It is typically used in combination with myrrh (mò yào).
In traditional Arab medicine (Tibb al-Nabawi and Unani medicine), frankincense was used for a remarkably similar set of conditions to Ayurveda — inflammatory joint disease, digestive complaints, respiratory conditions — suggesting that independent medical traditions arrived at comparable clinical conclusions through empirical observation.
Historical Timeline
Ancient Egyptian Use
Hieroglyphic records of frankincense in religious and embalming contexts. Trade routes from Punt (East Africa/Arabia) to Egypt established.
The Incense Road at Its Height
Frankincense trade dominates Arabian Peninsula commerce. Nabataean, Sabaean, and later Roman merchants build fortunes on the trade. Pliny the Elder documents enormous Roman consumption.
Codified in Ayurvedic Texts
Shallaki (Boswellia serrata) documented in Charaka Samhita and Sushruta Samhita for joint inflammation, respiratory conditions, and as a rasayana (rejuvenative).
Dioscorides Documents Medical Uses
De Materia Medica catalogs frankincense's medicinal applications — ulcers, hemorrhages, fevers — creating a reference used by physicians for over 1,500 years.
Enters Chinese Pharmacopoeia
Rǔxiāng (乳香) documented in Tang Dynasty TCM texts for pain, injury, and inflammatory conditions. Combined with myrrh in classical formulas still used today.
Western Pharmacological Research Begins
German researchers at the University of Tübingen (H.P. Ammon and colleagues) begin systematic investigation of boswellic acids. 5-LOX inhibition mechanism identified. First clinical trials in IBD conducted in Germany.
Boswellin Introduced to Western Markets
Sabinsa Corporation introduces Boswellin — the first standardized boswellia extract — to the US and European supplement markets, initiating the modern commercial era.
AKBA Identified as Primary Active Compound
Research groups isolate and characterize AKBA as the most potent 5-LOX inhibitor. Patented high-AKBA extracts (5-LOXIN, Aflapin) developed. Multiple OA clinical trials published.
Landmark Clinical Evidence
First MRI evidence of cartilage preservation (AprèsFlex, PLT). Multiple new RCTs. Growing interest in cognitive and neuroprotective applications via incensole acetate.
From Ancient Use to Modern Pharmacology
The modern scientific investigation of boswellia began in earnest in the 1980s, driven partly by Ayurvedic practitioners in India seeking to validate traditional uses through Western scientific methods, and partly by German phytomedicine researchers — particularly H.P. Ammon at the University of Tübingen — who systematically characterized the anti-inflammatory mechanisms of boswellic acids.
Ammon's group published foundational work identifying 5-lipoxygenase inhibition as the primary anti-inflammatory mechanism and establishing that AKBA was the most potent inhibitor — work that laid the pharmacological groundwork for everything that followed. The first standardized extract (Boswellin, Sabinsa Corporation) was introduced to Western markets in 1991.
What is striking in retrospect is how closely the traditional Ayurvedic and TCM indications for boswellia — joint inflammation, digestive inflammatory conditions, respiratory disease — correspond to the conditions where modern clinical evidence is strongest. Traditional healers, working through centuries of empirical observation and clinical practice, arrived at conclusions about boswellia's therapeutic range that modern pharmacology has largely confirmed.
Sustainability and Conservation
The increasing global demand for boswellia resin — driven by both the supplement industry and growing aromatherapy markets — has created unsustainable pressure on wild boswellia populations in several key growing regions. A landmark study published in Nature Sustainability (Bongers et al., 2019) warned that Boswellia papyrifera populations in Ethiopia were in steep decline due to over-tapping, bark damage, fire, and competition from invasive species, and projected a 50% decline in resin production over the following 15 years if practices did not change.
Boswellia serrata faces different but real pressures in India, including forest encroachment, unsustainable tapping frequency, and inadequate regeneration. Responsible sourcing is an important consideration when choosing supplements. Certifications such as FairWild, organic certification, and supplier transparency about harvest practices are meaningful quality indicators beyond just extract standardization.